Vitamin D for Sickle-cell Respiratory Complications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01443728
Recruitment Status : Active, not recruiting
First Posted : September 30, 2011
Last Update Posted : March 23, 2018
Information provided by (Responsible Party):
Gary M Brittenham, MD, Columbia University

September 27, 2011
September 30, 2011
March 23, 2018
December 2011
September 2015   (Final data collection date for primary outcome measure)
Respiratory events [ Time Frame: Every year for 2 years ]
Defined as respiratory infection, acute asthma exacerbation, and acute chest syndrome
Annual rate of respiratory events [ Time Frame: Up to 2 years ]
Various laboratory measurements for safety and monitoring of adverse events. Monthly oral vitamin D3 (100,000 IU [2.5 mg]), given to children and adolescents with sickle cell disease, will reduce the rate of respiratory events, defined as respiratory infections, exacerbations of asthma, and episodes of the acute chest syndrome.
Complete list of historical versions of study NCT01443728 on Archive Site
  • Pulmonary function tests [ Time Frame: Every year for 2 years ]
    Standard pulmonary function tests
  • Immune function [ Time Frame: Every 6 months for 2 years ]
    Serum cytokines to measure T-cell effector and regulatory function Measures of systemic inflammation [high-sensitivity C-reactive protein (hs-CRP), Whole Blood Count (WBC), platelets)
  • Bone function and bone turnover markers [ Time Frame: Every 6 months for 2 years ]
    Intact parathyroid hormone Serum C-terminal telopeptides of Type I collagen (CTX) Aminoterminal propeptide of Type 1 procollagen (P1NP)
  • Muscle strength [ Time Frame: Every year for 2 years ]
    Hand grip
Not Provided
Not Provided
Not Provided
Vitamin D for Sickle-cell Respiratory Complications
Vitamin D for Sickle-cell Respiratory Complications

This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play important roles in the development of the lung problems in sickle cell disease. Emerging evidence shows that vitamin D helps the immune system to fight infection and to control inflammation and could potentially help prevent respiratory complications in patients with sickle cell disease. The investigators hypothesize that oral vitamin D3, 100,000 IU (2.5 mg), given once a month to a group of children and adolescents with sickle cell disease, will reduce the rate of respiratory events (infection, asthma exacerbation and acute chest syndrome) compared to the rate in a group given standard dose oral vitamin D3, 12,000 IU (0.3 mg) given once a month.

Funding Source - U.S. Food & Drug Administration, Office of Orphan Products Development

This study will be a Phase 2 double-blind randomized clinical trial in 80 patients with sickle cell disease, ages 3 to 20 years-old, comparing a 2-year monthly oral dose of vitamin D3, 100,000 IU (equivalent to 3,300 IU/day) to a standard monthly dose, 12,000 IU (400 IU/day) in reducing the rate of respiratory events (defined as respiratory infections, acute asthma exacerbation, and the acute chest syndrome) in children and adolescents with sickle cell disease in comparison with the rates of respiratory events over a baseline period of one year.

Eligible participants (130 patients) will initially be screened to determine their blood vitamin D levels (serum 25-hydroxyvitamin D). Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be eligible for randomization. At study entry, blood and urine samples will be collected for routine and special blood tests including tests on immune function, inflammation, and bone function. Children above 5 years old will also have lung function and muscle strength tests. Participants will be followed once a month to administer the study medication (oral vitamin D3) and to monitor any side effects from the study medication by history, examination and blood and urine tests. After 12 and 24 months of therapy, the same study procedures at study entry will be repeated.

This study could help establish oral vitamin D3 as a simple, low cost treatment to reduce respiratory complications in children and adolescents with sickle cell disease.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Sickle Cell Disease
  • Vitamin D Deficiency
  • Acute Chest Syndrome
  • Asthma
  • Respiratory Infections
  • Drug: Vitamin D3
    Vitamin D3 100,000 IU orally once a month
    Other Name: Cholecalciferol
  • Drug: Vitamin D3
    Vitamin D3 12,000 IU orally once a month
    Other Name: Cholecalciferol
  • Experimental: Vitamin D3 100,000 IU
    Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
    Intervention: Drug: Vitamin D3
  • Active Comparator: Vitamin D3 12,000 IU
    Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
    Intervention: Drug: Vitamin D3
Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, McMahon DJ, Nieves JW, Brittenham GM. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv. 2018 May 8;2(9):969-978. doi: 10.1182/bloodadvances.2017013979.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Same as current
July 2018
September 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of sickle cell disease (HbSS, HbSC, HbS Beta-thalassemia)
  • Age 3 to 20 years old

Exclusion Criteria:

  • Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)
  • Patient unable or unwilling to comply with requirements of the clinical trial
  • Participation in other therapeutic clinical trial
  • Current diagnosis of rickets
  • History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia
  • Current use of corticosteroids, excluding inhaled steroids
  • Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)
  • Therapy with thiazide diuretics or lithium carbonate
  • Known liver or renal disease
  • Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry
  • Patients on chronic red blood cell transfusion therapy
  • Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year
  • Pregnancy
Sexes Eligible for Study: All
3 Years to 20 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01FD003894 ( U.S. FDA Grant/Contract )
Not Provided
Not Provided
Gary M Brittenham, MD, Columbia University
Gary M Brittenham, MD
Not Provided
Principal Investigator: Gary Brittenham, MD Columbia University
Principal Investigator: Margaret T Lee, MD Columbia University
Columbia University
March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP